U.S. Justice Department Removes DHS Lawyer After Blunt Remarks in Minnesota Immigration Court 
Trump Extends AGOA Trade Program for Africa Through 2026, Supporting Jobs and U.S.-Africa Trade 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
The U.S. Food and Drug Administration (FDA) has authorized the marketing of six on! PLUS nicotine pouch products owned by Altria Group, marking the first approvals granted under the agency’s new pilot program designed to accelerate the review of certain tobacco-related products. The decision represents a significant milestone for the growing nicotine pouch market in the United States.
According to the FDA, the authorization applies specifically to six on! PLUS nicotine pouches manufactured by Helix Innovations LLC, a joint venture associated with Altria’s global on! PLUS portfolio. Altria submitted its premarket tobacco product applications for these products in June 2024, and the FDA cleared them under the pilot initiative launched in September to help streamline regulatory reviews.
The newly authorized on! PLUS nicotine pouches are available in mint, tobacco, and wintergreen flavors, with nicotine strengths of 6 mg and 9 mg. These products are now legally permitted for sale to adults in the U.S. The FDA emphasized that its decision was based on scientific evidence showing that the pouches contain lower levels of harmful chemicals compared to other smokeless tobacco products, which may translate into a reduced risk of cancer and other serious health conditions. The authorization is limited strictly to the approved products and does not extend to other Helix Innovations offerings.
Nicotine pouches are placed under the lip and do not involve combustion, inhalation, or the presence of tobacco leaf. As a result, they are widely viewed as among the lowest-risk alternatives to traditional smoking. This category has become the fastest-growing segment in the U.S. tobacco market as consumers increasingly seek smoke-free options.
Earlier in 2025, the FDA authorized 20 Zyn nicotine pouch products owned by Philip Morris International, making them the first in this category to receive U.S. market approval after a review process that lasted more than five years.
Following the FDA decision, Altria announced that on! PLUS will resume taking new retail orders in Florida, North Carolina, and Texas, as well as through e-commerce channels. While regulators continue to stress that nicotine products are intended only for adults, public health officials note that nicotine exposure during adolescence can negatively affect brain development related to attention, learning, mood, and impulse control.
